Metastatic Breast Cancer 2025 UPDATE
Two Onc Docs
00:00
Triple-Negative First-Line Treatment and Biomarker Testing
Kareen emphasizes PD-L1 testing, chemotherapy backbones, pembrolizumab for PD-L1 CPS≥10, and PARP inhibitors for BRCA-mutated cases.
Play episode from 08:13
Transcript
